Gilead hepatitis C drug sales edge past Wall Street estimates
February 02, 2016 at 16:20 PM EST
Feb 2 (Reuters) - Gilead Sciences Inc's sales of hepatitis C drugs beat Wall Street estimates in the fourth quarter, helping to push the biotechnology company's shares 2 percent higher on Tuesday.
